Effects of Tailored Risk Communications for Skin Cancer Prevention and Detection: The PennSCAPE Randomized Trial

Por Glanz, Karen, Volpicelli, Kathryn, Jepson, Christopher, Ming, Michael E., Schuchter, Lynn M., Armstrong, Katrina
Publicado no Cancer Epidemiol Biomarkers Prev (2014)

Melanoma Genetic Testing, Counseling, and Adherence to Skin Cancer Prevention and Detection Behaviors

Por Glanz, Karen, Volpicelli, Kathryn, Kanetsky, Peter A., Ming, Michael E., Schuchter, Lynn M., Jepson, Christopher, Domchek, Susan M., Armstrong, Katrina
Publicado em 2013

Report of a Phase I Evaluation of Dose and Schedule of Interleukin-1 Alpha and Cyclophosphamide in Patients with Advanced Tumors: An Eastern Cooperative Oncology Group Study (PX990...

Por Dutcher, Janice P., Neuberg, Donna, Atkins, Michael B., Tester, William J., Wadler, Scott, Stewart, James A., Chachoua, Abraham, Schuchter, Lynn M.
Publicado em 2014

Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma

Por Flaherty, Keith T., Lee, Sandra J., Zhao, Fengmin, Schuchter, Lynn M., Flaherty, Lawrence, Kefford, Richard, Atkins, Michael B., Leming, Philip, Kirkwood, John M.
Publicado no J Clin Oncol (2013)

Acute visual loss after ipilimumab treatment for metastatic melanoma

Por Wilson, Melissa A., Guld, Kelly, Galetta, Steven, Walsh, Ryan D., Kharlip, Julia, Tamhankar, Madhura, McGettigan, Suzanne, Schuchter, Lynn M., Fecher, Leslie A.
Publicado no J Immunother Cancer (2016)

Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers

Por Flaherty, Keith T., Hamilton, Betty K., Rosen, Mark A., Amaravadi, Ravi K., Schuchter, Lynn M., Gallagher, Maryann, Chen, Helen, Sehgal, Chandra, O’Dwyer, Peter J.
Publicado no Oncologist (2015)

Physician and Stakeholder Perceptions of Conflict of Interest Policies in Oncology

Por Lockhart, A. Craig, Brose, Marcia S., Kim, Edward S., Johnson, David H., Peppercorn, Jeffrey M., Michels, Dina L., Storm, Courtney D., Schuchter, Lynn M., Rathmell, W. Kimryn
Publicado no J Clin Oncol (2013)

Cancer Immunology Miniatures: Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma

Por Bajor, David L., Xu, Xiaowei, Torigian, Drew A., Mick, Rosemarie, Garcia, Laura R., Richman, Lee P., Desmarais, Cindy, Nathanson, Katherine L., Schuchter, Lynn M., Kalos, Michael, Vonderheide, Robert H.
Publicado no Cancer Immunol Res (2014)

Correlation of somatic mutations and clinical outcome in melanoma patients treated with carboplatin, paclitaxel, and sorafenib

Por Wilson, Melissa A., Zhao, Fengmin, Letrero, Richard, D’Andrea, Kurt, Rimm, David L., Kirkwood, John M., Kluger, Harriet M., Lee, Sandra J., Schuchter, Lynn M., Flaherty, Keith T., Nathanson, Katherine L.
Publicado em 2014

Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study

Por Chu, Emily Y., Wanat, Karolyn A., Miller, Christopher J., Amaravadi, Ravi K., Fecher, Leslie A., Brose, Marcia S., McGettigan, Suzanne, Giles, Lydia R., Schuchter, Lynn M., Seykora, John T., Rosenbach, Misha
Publicado no J Am Acad Dermatol (2012)

Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases

Por Amaravadi, Ravi K., Schuchter, Lynn M., McDermott, David F., Kramer, Amy, Giles, Lydia, Gramlich, Kristi, Carberry, Mary, Troxel, Andrea B., Letrero, Richard, Nathanson, Katherine L., Atkins, Michael B., O’Dwyer, Peter J., Flaherty, Keith T.
Publicado em 2009

Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3

Por Abel, Ethan V., Basile, Kevin J., Kugel, Curtis H., Witkiewicz, Agnieszka K., Le, Kaitlyn, Amaravadi, Ravi K., Karakousis, Giorgos C., Xu, Xiaowei, Xu, Wei, Schuchter, Lynn M., Lee, Jason B., Ertel, Adam, Fortina, Paolo, Aplin, Andrew E.
Publicado em 2013

Copy number changes are associated with response to treatment with carboplatin, paclitaxel and sorafenib in melanoma

Por Wilson, Melissa A., Zhao, Fengmin, Khare, Sanika, Roszik, Jason, Woodman, Scott E., D'Andrea, Kurt, Wubbenhorst, Bradley, Rimm, David L., Kirkwood, John M., Kluger, Harriet M., Schuchter, Lynn M., Lee, Sandra J., Flaherty, Keith T., Nathanson, Katherine L.
Publicado no Clin Cancer Res (2015)

Enhancing the evaluation of PI3K inhibitors through 3D melanoma models

Por Shannan, Batool, Chen, Quan, Watters, Andrea, Perego, Michela, Krepler, Clemens, Thombre, Rakhee, Li, Ling, Rajan, Geena, Peterson, Scott, Gimotty, Phyllis A., Wilson, Melissa, Nathanson, Katherine L., Gangadhar, Tara C., Schuchter, Lynn M., Weeraratna, Ashani T., Herlyn, Meenhard, Vultur, Adina
Publicado no Pigment Cell Melanoma Res (2016)

American Society of Clinical Oncology Policy Statement Update: The Critical Role of Phase I Trials in Cancer Research and Treatment

Por Weber, Jeffrey S., Levit, Laura A., Adamson, Peter C., Bruinooge, Suanna, Burris, Howard A., Carducci, Michael A., Dicker, Adam P., Gönen, Mithat, Keefe, Stephen M., Postow, Michael A., Thompson, Michael A., Waterhouse, David M., Weiner, Susan L., Schuchter, Lynn M.
Publicado no J Clin Oncol (2015)

Collapse of the CD27+ B cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers

Por Carpenter, Erica L., Mick, Rosemarie, Rech, Andrew J., Beatty, Gregory L., Colligon, Theresa A., Rosenfeld, Myrna R., Kaplan, David E., Chang, Kyong-Mi, Domchek, Susan M., Kanetsky, Peter A., Fecher, Leslie A., Flaherty, Keith T., Schuchter, Lynn M., Vonderheide, Robert H.
Publicado em 2009

Oncogenic BRAF-mediated Melanoma Cell Invasion

Por Lu, Hezhe, Liu, Shujing, Zhang, Gao, Kwong, Lawrence N., Zhu, Yueyao, Miller, John P., Hu, Yi, Zhong, Wenqun, Zeng, Jingwen, Wu, Lawrence, Krepler, Clemens, Sproesser, Katrin, Xiao, Min, Xu, Wei, Karakousis, Giorgos C., Schuchter, Lynn M., Field, Jeffery, Zhang, Paul J., Herlyn, Meenhard, Xu, Xiaowei, Guo, Wei
Publicado no Cell Rep (2016)

Targeting ER stress–induced autophagy overcomes BRAF inhibitor resistance in melanoma

Por Ma, Xiao-Hong, Piao, Sheng-Fu, Dey, Souvik, Mcafee, Quentin, Karakousis, Giorgos, Villanueva, Jessie, Hart, Lori S., Levi, Samuel, Hu, Janice, Zhang, Gao, Lazova, Rossitza, Klump, Vincent, Pawelek, John M., Xu, Xiaowei, Xu, Wei, Schuchter, Lynn M., Davies, Michael A., Herlyn, Meenhard, Winkler, Jeffrey, Koumenis, Constantinos, Amaravadi, Ravi K.
Publicado em 2014

Personalized pre-clinical trials in BRAF inhibitor resistant patient derived xenograft models identify second line combination therapies

Por Krepler, Clemens, Xiao, Min, Sproesser, Katrin, Brafford, Patricia, Shannan, Batool, Beqiri, Marilda, Liu, Qin, Xu, Wei, Garman, Bradley, Nathanson, Katherine L., Xu, Xiaowei, Karakousis, Giorgos, Mills, Gordon B., Lu, Yiling, Ahmed, Tamer A., Poulikakos, Poulikos I., Caponigro, Giordiano, Boehm, Markus, Peters, Malte, Schuchter, Lynn M., Weeraratna, Ashani T., Herlyn, Meenhard
Publicado no Clin Cancer Res (2015)

BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth

Por Wang, Tao, Xiao, Min, Ge, Yingbin, Krepler, Clemens, Belser, Eric, Lopez-Coral, Alfonso, Xu, Xiaowei, Zhang, Gao, Azuma, Rikka, Liu, Qin, Liu, Rui, Li, Ling, Amaravadi, Ravi K., Xu, Wei, Karakousis, Giorgos, Gangadhar, Tara C., Schuchter, Lynn M., Lieu, Melissa, Khare, Sanika, Halloran, Molly B., Herlyn, Meenhard, Kaufman, Russel E.
Publicado no Clin Cancer Res (2015)